CEL-SCI Corporation (CVM) Stock Score, Valuation & Financial Research

CEL-SCI Corporation is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CVM

CEL-SCI Corporation does not currently have a complete Wall Street Score. The stored market price is USD 2.06. These figures are a research snapshot, not a buy or sell recommendation.

What CEL-SCI Corporation does

CEL-SCI Corporation (CVM) focuses on the research and development of immune-based therapies to combat cancer and various infectious diseases. Its flagship immunotherapy candidate, Multikine, is currently undergoing Phase III clinical trials for the treatment of head and neck cancer. The company also develops and holds the patent for its preclinical Ligand Epitope Antigen Presentation System (LEAPS), an innovative T-cell modulation technology. This system is designed to stimulate the human immune system to fight a broad range of conditions, including bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and various cancers. CEL-SCI's pipeline further includes LEAPS-H1N1-DC, along with LEAPS COV-19, an experimental therapy targeting the COVID-19 coronavirus. Additionally, the company is advancing CEL-2000 and CEL-4000 as potential treatments for rheumatoid arthritis. In a collaborative effort, CEL-SCI has partnered with the University of Georgia's Center for Vaccines and Immunology to progress the LEAPS COVID-19 immunotherapy. Established in 1983, the company's headquarters are located in Vienna, Virginia.

Company business and revenue

Research reporting period: 2025-09-30. A research update is not a new financial filing.

How the company makes money

CEL-SCI is a clinical-stage biotechnology company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity and debt offerings to fund the research and development of its proprietary immunotherapy candidates, specifically Multikine, which is intended to treat cancer and other diseases.

Products and services

  • The company's primary product candidate is Multikine (Leukocyte Interleukin, Injection), an investigational immunotherapy designed to stimulate the immune system to fight cancer, currently in clinical development.

Brands and product families

  • Multikine — The company's lead investigational immunotherapy candidate. Source

Customer types

Clinical trial participants.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturers for the production of its clinical trial materials and investigational drugs. Source

Business strengths to evaluate

  • Proprietary immunotherapy technology platform Source

Business risks and research considerations

  • History of operating losses and dependence on external financing Source
  • Uncertainty regarding regulatory approval for Multikine Source
  • Reliance on third-party clinical trial sites and contract manufacturers Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CVM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 2.06
Market capitalization:
14.16M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -22.7M
Free cash flow:
USD -17.16M
Cash:
USD 6.53M
Total debt:
USD 7.89M
EPS:
USD -2.58

What stands out

  • Free cash flow is USD -17.16M, negative for the stored period.
  • The balance sheet shows USD 6.53M of cash versus USD 7.89M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 1.37M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CVM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CVM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Does CVM's balance between cash and debt leave enough flexibility if business conditions weaken?
  • What specifically needs to improve for CVM to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CVM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research CVM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.